The global AI in clinical trials market was valued at USD 2 billion in 2025 and is projected to reach USD 7.32 billion by 2034, expanding at a 15.5% compound annual growth rate from 2026 to 2034, according to Maximize Market Research. Adoption is increasing as pharmaceutical and biotechnology companies, contract research organizations, hospitals and research institutes use artificial intelligence for patient screening, cohort selection, trial design, clinical data analysis, safety monitoring, drug discovery and personalized medicine. Machine learning, natural language processing and deep learning are being deployed across Phase I, Phase II and Phase III trials. North America leads the market, with the United States as the key regional market, while Europe and Asia Pacific — particularly China, India and Japan — are expanding. Decentralized trials, AI-driven patient monitoring, real-world evidence and AI-enabled drug discovery are creating opportunities, while data privacy, regulatory compliance, data quality and shortages of specialized expertise remain challenges.